EUVIMEDEUVIMED entdecken
Crossref

mTORC1 Selective Nano‐Inhibitor by Disrupting the Lysosomal Arginine‐SLC38A9‐ mTORC1‐CDKs Axis for Precision Bladder Cancer Therapy

Lulu Kong, Kaikai Xu, Xinlu Bao, Kebin Ye, Di Fan, Ning Wang, Yongming Deng, Wei Wang, Shaohua Wei, Lin Zhou iD

Advanced Materials · 2025-10 · 37 (39)

DOI: 10.1002/adma.202504798 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 04.07.2025. Verfasst von Lulu Kong und 9 weiteren Autor:innen. Beteiligte Einrichtung: National and Local Joint Engineering Research Center of Biomedical Functional Materials, School of Chemistry and Materials Science, Nanjing Normal Un…. Hauptthemen laut MEDLINE: Mechanistic Target of Rapamycin Complex 1, Lysosomes. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Foundation of Jiangsu Collaborative Innovation Centre of Biomedical Functional Materials.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The absence of precise targeting and defined mechanisms, akin to small molecules, remains a major barrier to the clinical translation of nanomedicines. Mammalian target of rapamycin complex 1 (mTORC1), a key regulator of cell proliferation and metabolism, is linked to abnormal activation in various diseases like cancers. While small‐molecule inhibitors of mTORC1 are limited, they remain a focus. Here, a strategy is presented for mTORC1‐specific nano‐inhibitors targeting the lysosomal arginine (Arg)‐SLC38A9‐mTORC1 pathway. Using [2Fe‐2S]CO 6 as a universal paradigm, nanomedicines are developed (e.g., ZnPc‐SFeCO) that degrade Arg in the lysosome, inhibiting SLC38A9 activation and blocking mTORC1 recruitment. ZnPc‐SFeCO inhibits mTORC1 at ultra‐low concentrations (1.07 ng mL −1 ), with three orders of magnitude greater specificity than the clinical small molecule rapamycin. SLC38A9 knockout abolishes nanomedicine efficacy. Differential responses to the inhibitors are also observed in normal and bladder cancer cells, linked to SLC38A9 expression levels, suggesting potential for precise treatment of non‐muscle invasive bladder cancer (NMIBC). In vivo, ZnPc‐SFeCO combined with photodynamic therapy outperformed MMC in preventing tumor recurrence and extending survival. This work establishes a promising approach for developing mTORC1‐specific nano‐inhibitors with well‐defined targets and mechanisms, offering new insights into the development of precision nanomedicines for cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mechanistic Target of Rapamycin Complex 1LysosomesAntineoplastic AgentsCell Line, TumorUrinary Bladder NeoplasmsHumansAnimalsMiceNanomedicineArginine

Stichwörter der Autor:innen

ArgSLC38A9cancermTORC1nano‐inhibitors

Substanzen

Mechanistic Target of Rapamycin Complex 1Antineoplastic AgentsArginine

Autor:innen und Institutionen

  • National and Local Joint Engineering Research Center of Biomedical Functional Materials, School of Chemistry and Materials Science, Nanjing Normal University, Nanjing, 210023, China.
  • School of Science, Key Laboratory of High Performance Scientific Computation, Xihua University, Chengdu, 610039, China.
  • Department of Urology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China.
  • School of Chemistry and Chemical Engineering, Yancheng Institute of Technology, Yancheng, 224051, China.

ORCID-Profile: Lin Zhou

Förderung

  • National Natural Science Foundation of China
  • Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
  • Foundation of Jiangsu Collaborative Innovation Centre of Biomedical Functional Materials

Zitieren

APA

Kong, L., Xu, K., Bao, X., Ye, K., Fan, D., Wang, N., Deng, Y., Wang, W., Wei, S., & Zhou, L. (2025). mTORC1 Selective Nano‐Inhibitor by Disrupting the Lysosomal Arginine‐SLC38A9‐ mTORC1‐CDKs Axis for Precision Bladder Cancer Therapy. Advanced Materials, 37(39). https://doi.org/10.1002/adma.202504798

Vancouver

Kong L, Xu K, Bao X, Ye K, Fan D, Wang N, et al. mTORC1 Selective Nano‐Inhibitor by Disrupting the Lysosomal Arginine‐SLC38A9‐ mTORC1‐CDKs Axis for Precision Bladder Cancer Therapy. Advanced Materials. 2025;37(39). doi:10.1002/adma.202504798

BibTeX
@article{Kong2025,
  author = {Kong, Lulu and Xu, Kaikai and Bao, Xinlu and Ye, Kebin and Fan, Di and Wang, Ning and Deng, Yongming and Wang, Wei and Wei, Shaohua and Zhou, Lin},
  title = {mTORC1 Selective Nano‐Inhibitor by Disrupting the Lysosomal Arginine‐SLC38A9‐ mTORC1‐CDKs Axis for Precision Bladder Cancer Therapy},
  journal = {Advanced Materials},
  year = {2025},
  volume = {37},
  number = {39},
  doi = {10.1002/adma.202504798}
}
Kostenlos starten →